WO2008151040A2 - Produit médical enrobé d'analgésique - Google Patents

Produit médical enrobé d'analgésique Download PDF

Info

Publication number
WO2008151040A2
WO2008151040A2 PCT/US2008/065356 US2008065356W WO2008151040A2 WO 2008151040 A2 WO2008151040 A2 WO 2008151040A2 US 2008065356 W US2008065356 W US 2008065356W WO 2008151040 A2 WO2008151040 A2 WO 2008151040A2
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic
medical product
ecm
submucosa
tissue contacting
Prior art date
Application number
PCT/US2008/065356
Other languages
English (en)
Other versions
WO2008151040A3 (fr
Inventor
Michael C. Hiles
Paul J. Hall
Original Assignee
Cook Biotech Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Biotech Incorporated filed Critical Cook Biotech Incorporated
Publication of WO2008151040A2 publication Critical patent/WO2008151040A2/fr
Publication of WO2008151040A3 publication Critical patent/WO2008151040A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine

Definitions

  • the present invention resides generally in the field of medical products and in particular aspects to medical products useful, for example, in pain relief.
  • ECM extracellular matrix
  • the present invention provides such medical products, as well as methods of preparing and using the same.
  • the present invention provides a medical product including a collagenous extracellular matrix (ECM) material and an analgesic selected from the group consisting of lidocaine, bupivacaine, or a mixture thereof.
  • ECM extracellular matrix
  • an analgesic selected from the group consisting of lidocaine, bupivacaine, or a mixture thereof.
  • the ECM material comprises submucosa of a warm-blooded vertebrate.
  • the present invention provides a medical product useful in pain relief.
  • the medical product includes a sheet comprising small intestinal submucosa.
  • the sheet incorporates an analgesic selected from the group consisting of lidocaine, bupivicaine, or a mixture thereof.
  • an analgesic selected from the group consisting of lidocaine, bupivicaine, or a mixture thereof.
  • the present invention provides a method for preparing a medical product.
  • the method includes providing a sheet of a collagenous extracellular matrix (ECM) material.
  • An analgesic is applied to at least a portion of the ECM material.
  • the analgesic is applied to at least a portion of a tissue contacting surface of the ECM material.
  • the analgesic is applied to the ECM material as a whole.
  • the ECM material comprises submucosa of a warm-blooded vertebrate.
  • the present invention provides a method for treating a patient.
  • the method includes providing a sheet of a collagenous extracellular matrix (ECM) material.
  • An analgesic is applied to at least a portion of the ECM material.
  • the analgesic is applied to at least a portion of a tissue contacting_surface of the ECM material.
  • the analgesic is applied to the ECM material as a whole.
  • the medical product is applied to the patient so as to treat the patient.
  • the ECM material comprises submucosa of a warm-blooded vertebrate.
  • the present invention provides a medical product.
  • the medical product includes a collagenous extracellular matrix (ECM) material, a carrier, and one or more analgesic agents.
  • ECM extracellular matrix
  • the carrier and the analgesic agent(s) are incorporated on or in the ECM material.
  • the carrier is effective to extend the duration of release of the agent(s) from the ECM material.
  • the medical product can further include a polymer film or layer over any portion of the ECM material containing the analgesic agent(s).
  • Fig. 1 provides a perspective view of a medical product of the invention containing a sheet of a collagenous extracellular matrix (ECM) material including an analgesic coating.
  • ECM extracellular matrix
  • Fig. 2 provides a perspective view of a medical producing of the invention containing multiple sheets of a collagenous extracellular matrix (ECM) material including an analgesic coating.
  • ECM extracellular matrix
  • the present invention provides medical products useful in a wide variety of medical applications.
  • Such medical products include a collagenous extracellular matrix (ECM) material and an analgesic, and preferably an analgesic selected from the group consisting of lidocaine, buvivacaine, or a mixture thereof.
  • ECM extracellular matrix
  • the medical product 10 includes a sheet of a collagenous ECM material 11 having a first surface 12 and a second surface 13 opposing the first surface.
  • the second surface 13 includes a coating comprising an analgesic selected from the group consisting of lidocaine, buvivacaine, or a mixture thereof.
  • the first surface 12 can also include a coating comprising the analgesic(s), or that medical product 10 as a whole can incorporate the analgesic(s) generally homogenously in its structure.
  • Fig. 2 illustrates a similar medical product 20 formed of multiple sheets 21 and 22 of a collagenous ECM material.
  • the multiple sheets of a collagenous ECM material are bonded together to form a laminate.
  • the first surface 24 of the laminate includes a coating comprising the analgesic(s) and the second surface 26 of the laminate includes a coating of the analgesic(s).
  • either the first surface 24 or the second surface 26 can include a coating of the analgesic(s).
  • the laminate includes the analgesic(s) incorporated substantially homogenously in its structure, and/or in between sheets of the laminate.
  • Medical products of the invention can be used to treat a variety of medical conditions, including those which cause pain to a patient.
  • a medical product of the invention can be used as a pain reliever and can either be applied to an external structure of a patient (e.g., skin) or can be implanted within a patient, for example to provide tissue support as in the case of hernia repair.
  • a medical product of the invention can be configured in a variety of forms to suit its desired site of use.
  • a medical product of the invention is useful in surgery, for correction of physical defects of a patient.
  • One advantage of using a collagenous ECM material in the medical products of the invention is that they can elute substances contained therein or thereon locally thereby eliminating or diminishing the need for systemic administration of the substance and minimizing the risk of systemic toxicity and adverse reactions.
  • the medical product of the invention when configured for application to tissue, is cut or otherwise configured to a desired size for its end use.
  • the medical product is preferably sized larger than the tissue defect to which it is applied. Sizing the medical product in this way allows for easy attachment to the surrounding tissue.
  • the medical product can be more securely attached to the surrounding tissue or other structure using any of several known suitable attachment means.
  • suitable attachment means include, for example, stapling, suturing, bonding and the like.
  • the medical product is securely attached to the surrounding tissue or other structure by sutures or staples.
  • sutures comprising ProleneTM, VicrylTM, MersileneTM, PanacrylTM, and MonocrylTM, are contemplated for use in the invention.
  • Other suture materials are well known to those skilled in the art.
  • Medical adhesives as generally known in the art can also be used in conjunction with the medical products of the invention.
  • the medical product of the invention can be packaged in a dehydrated or hydrated state.
  • Dehydration of a medical product of the invention can be achieved by any means known in the art.
  • dehydration is accomplished by either lyophilization or vacuum pressing and can simultaneously be utilized to bond layers of collagenous ECM material together.
  • Any suitable solution can then optionally be used to rehydrate the medical product prior to use.
  • the rehydration solution comprises water or buffered saline.
  • the medical product can be crosslinked.
  • a medical product can be crosslinked once formed, or the collagenous ECM material can be crosslinked prior to applying the analgesic(s) to the material, or both.
  • Increasing the amount (or number) of crosslinkages within the medical product and/or between two or more layers of the medical product can be used to enhance its strength.
  • introduced crosslinkages within the medical product may also affect its remodelability. Consequently, in certain embodiments, the material used in a medical product will substantially retain its native level of crosslinking, or the amount of added crosslinkages within the material can be judiciously selected depending upon the desired treatment regime. In many cases, the material will exhibit remodelable properties such that the remodeling process occurs over the course of several days or several weeks.
  • the remodeling process occurs within a matter of about 5 days to about 12 weeks.
  • introduced crosslinking of the medical product may be achieved by photo-crosslinking techniques, or by the application of a crosslinking agent, such as by chemical crosslinkers, or by protein crosslinking induced by dehydration or other means.
  • Chemical crosslinkers that may be used include for example aldehydes such as glutaraldehydes, diimides such as carbodiimides, e.g., l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, diisocyanates, such as hexamethylene-diisocyanate, ribose or other sugars, acyl-azide, sulfo-N-hydroxysuccinamide, or polyepoxide compounds, including for example polyglycidyl ethers such as ethyleneglycol diglycidyl ether, available under the trade name DENACOL EX810 from Nagese Chemical Co., Osaka, Japan, and glycerol polyglycerol ether available under the trade name DENACOL EX 313 also from Nagese Chemical Co. Typically, when used, polyglycerol ethers or other polyepoxide compounds will have from 2 to about 10 ep
  • the layers of the laminate can be additionally crosslinked to bond multiple layers of a collagenous ECM material to one another.
  • additional crosslinking may be added to individual layers prior to coupling to one another, during coupling to one another, and/or after coupling to one another.
  • a remodelable material for use in the medical products and methods of the present invention, and particular advantage can be provided by including a remodelable collagenous material.
  • Such remodelable collagenous materials can be provided, for example, by collagenous materials isolated from a suitable tissue source from a warm-blooded vertebrate, and especially a mammal. Reconstituted or naturally-derived collagenous materials can be used in the present invention. Such materials that are at least bioresorbable will provide advantage in the present invention, with materials that are bioremodelable and promote cellular invasion and ingrowth providing particular advantage. Remodelable materials may be used in this context to promote cellular growth within the site in which a medical product of the invention is implanted. Moreover, the thickness of the medical product can be adjusted to control the extent of cellular ingrowth.
  • Suitable bioremodelable materials can be provided by collagenous extracellular matrix materials (ECMs) possessing biotropic properties, including in certain forms angiogenic collagenous extracellular matrix materials.
  • ECMs extracellular matrix materials
  • suitable collagenous materials include ECMs containing materials such as submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane layers, including liver basement membrane.
  • Suitable submucosa-containing materials for these purposes include, for instance, materials containing intestinal submucosa, including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.
  • the submucosa can be derived from any suitable organ or other biological structure, including for example submucosa derived from the alimentary, respiratory, intestinal, urinary or genital tracts of warm-blooded vertebrates.
  • Submucosa useful in the present invention can be obtained by harvesting such tissue sources and delaminating the submucosa from smooth muscle layers, mucosal layers, and/or other layers occurring in the tissue source.
  • submucosa useful in the present invention and its isolation and treatment, reference can be made, for example, to U.S. Patent Nos. 4,902,508, 5,554,389, 5,993,844, 6,206,931, and 6,099,567.
  • a submucosa or other ECM material having differing characteristic sides When a submucosa or other ECM material having differing characteristic sides is used in combination with a medical device, e.g., a surgical stapler, it can be oriented upon the medical device with a specified side directed outward for contact with the arm(s) of the surgical fastening device.
  • a medical device e.g., a surgical stapler
  • the material may be oriented with either the luminal or abluminal side facing outwardly for contact with the arm(s) of the surgical fastening device.
  • the submucosa-containing material and any other ECM used may optionally retain growth factors or other bioactive components native to the source tissue.
  • the submucosa or other ECM may include one or more native growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), and/or platelet derived growth factor (PDGF).
  • FGF-2 basic fibroblast growth factor
  • TGF-beta transforming growth factor beta
  • EGF epidermal growth factor
  • PDGF platelet derived growth factor
  • submucosa or other ECM used in the invention may include other biological materials such as heparin, heparin sulfate, hyaluronic acid, f ⁇ bronectin and the like.
  • the submucosal or other ECM material may include a native bioactive component that induces, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or
  • Submucosal or other ECM materials of the present invention can be derived from any suitable organ or other tissue source, usually sources containing connective tissues.
  • the ECM materials processed for use in the invention will typically include abundant collagen, most commonly being constituted at least about 80% by weight collagen on a dry weight basis.
  • Such naturally-derived ECM materials will for the most part include collagen fibers that are non-randomly oriented, for instance occurring as generally uniaxial or multi-axial but regularly oriented fibers.
  • the ECM material can retain these components interspersed as solids between, upon and/or within the collagen fibers.
  • Particularly desirable naturally-derived ECM materials for use in the invention will include significant amounts of such interspersed, non- collagenous solids that are readily ascertainable under light microscopic examination.
  • non-collagenous solids can constitute a significant percentage of the dry weight of the ECM material in certain inventive embodiments, for example at least about 1%, at least about 3%, and at least about 5% by weight in various embodiments of the invention.
  • the submucosal or other ECM material used in the present invention may also exhibit an angiogenic character and thus be effective to induce angiogenesis in a host engrafted with a device including the material.
  • angiogenesis is the process through which the body makes new blood vessels to generate increased blood supply to tissues.
  • angiogenic materials when contacted with host tissues, promote or encourage the formation of new blood vessels.
  • Methods for measuring in vivo angiogenesis in response to biomaterial implantation have recently been developed. For example, one such method uses a subcutaneous implant model to determine the angiogenic character of a material. See, C. Heeschen et al., Nature Medicine 7 (2001), No. 7, 833-839. When combined with a fluorescence microangiography technique, this model can provide both quantitative and qualitative measures of angiogenesis into biomaterials. C. Johnson et al., Circulation Research 94 (2004), No. 2, 262-268.
  • non-native bioactive components such as those synthetically produced by recombinant technology or other methods, may be incorporated into the submucosa or other ECM tissue.
  • These non-native bioactive components may be naturally-derived or recombinantly produced proteins that correspond to those natively occurring in the ECM tissue, but perhaps of a different species (e.g. human proteins applied to collagenous ECMs from other animals, such as pigs).
  • the non-native bioactive components may also be drug substances.
  • Illustrative drug substances that may be incorporated into and/or onto the ECM materials used in the invention include, for example, antibiotics, thrombus-promoting substances such as blood clotting factors, e.g.
  • thrombin, fibrinogen, and the like may be applied to the ECM material as a premanufactured step, immediately prior to the procedure (e.g. by soaking the material in a solution containing a suitable antibiotic such as cefazolin), or during or after engraftment of the material in the patient.
  • a non-native bioactive component can be included in the analgesic coating of the medical product.
  • the non-native bioactive component can be added at any point during preparation of the medical product, including being mixed with one or all of the analgesic coating components prior to application of the analgesic to a medical product or, alternatively, after the analgesic is formed and applied.
  • a non-native bioactive component can be applied to a submucosa or other ECM tissue by any suitable means. Suitable means include, for example, spraying, impregnating, dipping, etc.
  • the non-native bioactive component can be applied to the ECM tissue either before or after the analgesic is applied to the material, or both.
  • the non-native bioactive component can be applied either before, in conjunction with, or after these other components.
  • Submucosa or other ECM tissue used in the invention is preferably highly purified, for example, as described in U.S. Patent No. 6,206,931 to Cook et al.
  • preferred ECM material will exhibit an endotoxin level of less than about 12 endotoxin units (EU) per gram, more preferably less than about 5 EU per gram, and most preferably less than about 1 EU per gram.
  • EU endotoxin units
  • the submucosa or other ECM material may have a bioburden of less than about 1 colony forming units (CFU) per gram, more preferably less than about 0.5 CFU per gram.
  • CFU colony forming units
  • Fungus levels are desirably similarly low, for example less than about 1 CFU per gram, more preferably less than about 0.5 CFU per gram.
  • Nucleic acid levels are preferably less than about 5 ⁇ g/mg, more preferably less than about 2 ⁇ g/mg, and virus levels are preferably less than about 50 plaque forming units (PFU) per gram, more preferably less than about 5 PFU per gram.
  • PFU plaque forming units
  • such expanded materials can be formed by the controlled contact of an ECM material with one or more alkaline substances until the material expands, and the isolation of the expanded material.
  • the contacting can be sufficient to expand the ECM material to at least 120% of (i.e. 1.2 times) its original bulk volume, or in some forms to at least about two times its original volume.
  • the expanded material can optionally be isolated from the alkaline medium, e.g. by neutralization and/or rinsing.
  • the collected, expanded material can be used in any suitable manner in the preparation of a medical device.
  • the expanded material can be enriched with bioactive components, dried, and/or molded, etc., in the formation of a graft construct of a desired shape or configuration.
  • a medical graft material and/or device formed with the expanded ECM material can be highly compressible (or expandable) such that the material can be compressed for delivery, such as from within the lumen of a cannulated delivery device, and thereafter expand upon deployment from the device so as to become anchored within a patient and/or cause closure of a tract within the patient.
  • Expanded collagenous or ECM materials can be formed by the controlled contact of a collagenous or ECM material with an aqueous solution or other medium containing sodium hydroxide.
  • Alkaline treatment of the material can cause changes in the physical structure of the material that in turn cause it to expand. Such changes may include denaturation of the collagen in the material.
  • the magnitude of the expansion is related to several factors, including for instance the concentration or pH of the alkaline medium, exposure time, and temperature used in the treatment of the material to be expanded.
  • ECM materials that can be processed to make expanded materials can include any of those disclosed herein or other suitable ECM's.
  • Typical such ECM materials will include a network of collagen fibrils having naturally-occurring intramolecular cross links and naturally-occurring intermolecular cross links.
  • the naturally-occurring intramolecular cross links and naturally-occurring intermolecular cross links can be retained in the processed collagenous matrix material sufficiently to maintain the collagenous matrix material as an intact collagenous sheet material; however, collagen fibrils in the collagenous sheet material can be denatured, and the collagenous sheet material can have an alkaline -processed thickness that is greater than the thickness of the starting material, for example at least 120% of the original thickness, or at least twice the original thickness.
  • the concentration of the alkaline substance for treatment of the remodelable material can be in the range of about 0.5 to about 4 M, with a concentration of about 1 M to about 3 M being more preferable.
  • the pH of the alkaline substance can in certain embodiments range from about 8 to about 14.
  • the alkaline substance will have a pH of from about 10 to about 14, and most preferably of from about 12 to about 14.
  • the exposure of the collagenous material to the alkaline substance is performed at a temperature of about 4 to about 45 0 C. In preferred embodiments, the exposure is performed at a temperature of about 25 to about 40 0 C, with 37 0 C being most preferred.
  • the exposure time can range from at least about one minute up to about 5 hours or more. In some embodiments, the exposure time is about 1 to about 2 hours. In a particularly preferred embodiment, the collagenous material is exposed to a 3 M solution of NaOH having a pH of 14 at a temperature of about 37 0 C for about 1.5 to 2 hours.
  • Such treatment results in collagen denaturation and a substantial expansion of the remodelable material.
  • Denaturation of the collagen matrix of the material can be observed as a change in the collagen packing characteristics of the material, for example a substantial disruption of a tightly bound collagenous network of the starting material.
  • a non-expanded ECM or other collagenous material can have a tightly bound collagenous network presenting a substantially uniform, continuous surface when viewed by the naked eye or under moderate magnification, e.g. 10Ox magnification.
  • an expanded collagenous material can have a surface that is quite different, in that the surface is not continuous but rather presents collagen strands or bundles in many regions that are separated by substantial gaps in material between the strands or bundles when viewed under the same magnification, e.g.
  • an expanded collagenous material typically appears more porous than a corresponding non-expanded collagenous material.
  • the expanded collagenous material can be demonstrated as having increased porosity, e.g. by measuring for an increased permeability to water or other fluid passage as compared to the non-treated starting material.
  • the more foamy and porous structure of an expanded ECM or other collagenous material can allow the material to be cast or otherwise prepared into a variety of sponge or foam shapes for use in the preparation of medical materials and devices. It can further allow for the preparation of constructs that are highly compressible and which expand after compression. Such properties can be useful, for example, when the prepared medical graft material is to be compressed and loaded into a deployment device (e.g. a lumen thereof) for delivery into a patient, and thereafter deployed to expand at the implant site.
  • a deployment device e.g. a lumen thereof
  • the material can be isolated from the alkaline medium and processed for further use.
  • the collected material can be neutralized and/or rinsed with water to remove the alkalinity from the material, prior to further processing of the material to form a medical product of the invention.
  • a starting ECM material i.e., prior to treatment with the alkaline substance
  • controlled treatment of the remodelable material with an alkaline substance will be sufficient to create a remodelable collagenous material which is substantially devoid of nucleic acids and lipids, and potentially also of growth factors, glycoproteins, glycosaminoglycans, and proteoglycans. This may be true for other processing techniques as discussed herein, such as the controlled treatment of the material with a detergent.
  • one or more bioactive components exogenous or endogenous, for example, similar to those removed from an ECM material (i.e., both non-expanded and expanded materials) during processing, can be returned to the material.
  • an ECM material can include a collagenous material which has been depleted of nucleic acids and lipids, but which has been replenished with growth factors, glycoproteins, glycosaminoglycans, and/or proteoglycans.
  • These bioactive components can be returned to the material by any suitable method. For instance, in certain forms a tissue extract, such as is discussed in U.S. Patent No. 6,375,989, containing these components can be prepared and applied to an ECM collagenous material.
  • the ECM can be incubated in a tissue extract for a sufficient time to allow bioactive components contained therein to associate with the ECM material.
  • the tissue extract may, for example, be obtained from non-expanded collagenous tissue of the same type used to prepare the expanded material.
  • Other means for returning or introducing bioactive components to an ECM material include spraying, impregnating, dipping, etc. as known in the art.
  • an ECM material may be modified by the addition of one or more growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF beta), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and/or cartilage derived growth factor (CDGF).
  • FGF-2 basic fibroblast growth factor
  • TGF beta transforming growth factor beta
  • EGF epidermal growth factor
  • PDGF platelet derived growth factor
  • CDGF cartilage derived growth factor
  • an ECM material may include a bioactive component that induces, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or gene expression similar to a non-expanded collagenous material.
  • a medical material can be provided in any suitable form prior to application of an analgesic thereto.
  • suitable forms include, for example, as one or more sheets or layers, as a foam, or as a sponge.
  • the form used will typically depend on a variety of factors including, but not limited to, the end use of the medical product and the type of material used (e.g., synthetic or biological).
  • the medical product will have a thickness in the range of about 50 to about 1000 microns, more preferably about 100 to 600 microns, and most preferably about 100 to about 350 microns.
  • the medical product will desirably exhibit a suture retention strength in the range of about 100 to about 1000 gram force, e.g. typically in the range of about 200 to about 600 gram force, each of these based upon 5-0 Prolene suture and a bite depth of 2 mm.
  • ECM collagenous tissue can be bonded together in any suitable fashion, including dehydrothermal bonding under heated, non-heated or lyophilization conditions, using adhesives as described herein, glues or other bonding agents, crosslinking with chemical agents or radiation (including UV radiation), or any combination of these with each other or other suitable methods.
  • said analgesic(s) can be applied to at least a portion of a collagenous ECM material by any suitable means. Suitable means include, for example, brushing, spraying, soaking, dipping, etc. In certain forms, a substantial portion of a surface of a medical material is coated with the adhesive. By “substantial portion” is meant that at least about 75% of a surface of a medical material is coated with an analgesic(s).
  • the analgesic(s) can be applied alone or in combination with a suitable carrier. In certain embodiments, the analgesic(s) is applied in conjunction with a biodegradable macro-molecular substance such as a biodegradable polymer.
  • Preferred such polymers include polylactic acid, polyglycolic acid, or copolymers thereof (PLGA).
  • a solution of the substances can be prepared in a solvent and the ECM device soaked in the solution, e.g. to allow a precipitate containing the polymer and analgesic(s) to be deposited upon and/or within the device.
  • the device can then be removed from the solution and further processed, e.g. dried, packaged and sterilized.
  • the analgesic(s) can be applied in conjunction with a biocompatible tissue adhesive.
  • Preferred tissue adhesives include, for example, biodegradable polymer hydrogels such as FOCALSEAL® (biodegradable eosin-PEG-lactide hydrogel requiring photopolymerization with Xenon light wand) produced by Focal; or natural polymer adhesives such as those containing fibrogen, e.g.
  • biodegradable polymer hydrogels such as FOCALSEAL® (biodegradable eosin-PEG-lactide hydrogel requiring photopolymerization with Xenon light wand) produced by Focal
  • natural polymer adhesives such as those containing fibrogen, e.g.
  • BERIP LAST® produced by Adventis-Bering
  • VIVOSTAT® produced by ConvaTec (Bristol-Meyers- Squibb)
  • SEALAGENTM produced by Baxter
  • FIBRX® containing virally inactivated human fibrinogen and inhibited- human thrombin
  • TIS SEEL® fibrin glue composed of plasma derivatives from the last stages in the natural coagulation pathway where soluble fibrinogen is converted into a solid fibrin
  • TISSUCOL® produced by Baxter
  • QUIXIL® Biological Active Component and Thrombin
  • Omrix Biopharm those comprising polyethylene glycol and/or collagen, such as a PEG-collagen conjugate produced by Cohesion (Collagen); or those containing cyanoacrylate such as HYSTOACRYL® BLUE (ENBUCRILATE) (cyanoacrylate) produced by Davis & Geek
  • NEXACRYLTM N-butyl cyanoacrylate
  • the biodegradable or biocompatible adhesive can be self-crosslinking (not requiring energy application for curing), or may require energy, such as radiation, for curing.
  • the biodegradable macro-molecular substance and/or biocompatible tissue adhesive can be effective to extend the time of release of the analgesic(s) from the ECM material.
  • an analgesic agent(s) that has been coated onto at least a portion of a surface of a collagenous ECM material from aqueous or turbulent environments, such as may be encountered when a medical product is implanted into a patient.
  • an analgesic is provided to an ECM material as discussed herein.
  • a synthetic or natural polymer solution can then be applied to any portion of the ECM material containing the analgesic(s), or applied over the ECM material as a whole, to mechanically entrap the analgesic(s) onto or within the ECM material.
  • an ECM material including an analgesic(s) can be dipped into a polymer solution.
  • the polymer solution can then be allowed to polymerize to form a polymer film or layer over the analgesic(s), thus entrapping the analgesic(s) onto or within the ECM material.
  • a polymer solution can be painted or sprayed over the ECM material including an analgesic to provide a film or layer over the surface of the ECM material for entrapping the analgesic(s) onto or within the ECM material.
  • a pre-cast polymer film or layer can be coupled to the ECM material including an analgesic by sewing, adhering, or otherwise attaching the film or layer to a surface of the ECM material including an analgesic.
  • Synthetic polymers useful for entrapping an analgesic to an ECM material can include, for example, polyhydroxyalkanoates, polycaprolactones, etc.
  • Natural polymers useful for entrapping an analgesic to an ECM material can include, for example, fibrin, collagen, etc.
  • An analgesic as used herein preferably includes lidocaine, bupivacaine, or a mixture thereof, all of which are commercially available.
  • the analgesic can be included in the medical product in an amount of about 0.01-0.5% (w/v), and preferably in an amount of about 0.1-0.2% (w/v). It will be understood that the amount of analgesic(s) can be varied to achieve the desired level of treatment.
  • the medical products of the invention can be provided in sterile packaging suitable for medical products. Sterilization may be achieved, for example, by irradiation, ethylene oxide gas, or any other suitable sterilization technique, and the materials and other properties of the medical packaging will be selected accordingly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des produits médicaux comprenant un analgésique tel que la lidocaïne, la bupivicaïne ou un mélange de celles-ci. De tels produits médicaux peuvent trouver une utilisation pour soulager la douleur, en particulier après une chirurgie, et peuvent être appliqués à un tissu ou peuvent être implantés dans un patient. Sont également décrits des produits médicaux comprenant un matériau de matrice extracellulaire, un ou plusieurs agents analgésiques, et un véhicule efficace pour étendre la libération de l'agent ou des agents. Des procédés apparentés de fabrication et d'utilisation sont également décrits.
PCT/US2008/065356 2007-05-31 2008-05-30 Produit médical enrobé d'analgésique WO2008151040A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94107307P 2007-05-31 2007-05-31
US60/941,073 2007-05-31

Publications (2)

Publication Number Publication Date
WO2008151040A2 true WO2008151040A2 (fr) 2008-12-11
WO2008151040A3 WO2008151040A3 (fr) 2009-11-12

Family

ID=39645323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/065356 WO2008151040A2 (fr) 2007-05-31 2008-05-30 Produit médical enrobé d'analgésique

Country Status (2)

Country Link
US (1) US20090142400A1 (fr)
WO (1) WO2008151040A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102698319A (zh) * 2012-03-02 2012-10-03 首都医科大学附属北京朝阳医院 一种抗肿瘤生物补片
US8845719B2 (en) 2011-05-27 2014-09-30 Cormatrix Cardiovascular, Inc Extracellular matrix material conduits and methods of making and using same
US8980296B2 (en) 2009-02-18 2015-03-17 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
WO2019113623A1 (fr) * 2017-12-11 2019-06-20 Animal Ethics Pty Ltd Pansement pour plaies

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257434B2 (en) 2007-12-18 2012-09-04 Cormatrix Cardiovascular, Inc. Prosthetic tissue valve
US8679176B2 (en) 2007-12-18 2014-03-25 Cormatrix Cardiovascular, Inc Prosthetic tissue valve
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165983A (en) * 1991-07-31 2000-12-26 Klaus; Edwin Use of collagen for the treatment of degenerative articular processes
WO2005097219A2 (fr) * 2004-03-31 2005-10-20 Cook Incorporated Materiau de greffe a base d'ecm
WO2006034568A1 (fr) * 2004-09-30 2006-04-06 Covalon Technologies Inc. Matrices de gelatine elastiques non-adhesives

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2127903A (en) * 1936-05-05 1938-08-23 Davis & Geck Inc Tube for surgical purposes and method of preparing and using the same
US2167251A (en) * 1938-08-20 1939-07-25 Davis & Geck Inc Surgical tape of submucosa tissue
US3272204A (en) * 1965-09-22 1966-09-13 Ethicon Inc Absorbable collagen prosthetic implant with non-absorbable reinforcing strands
US4321914A (en) * 1980-04-22 1982-03-30 W. L. Gore & Associates, Inc. Percutaneous conduit having PTFE skirt
US4969902A (en) * 1987-02-20 1990-11-13 Biagio Ravo Implantable device
US4781176A (en) * 1987-02-20 1988-11-01 Biagio Ravo Implantable device
US4956178A (en) * 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US5281422A (en) * 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5269774A (en) * 1992-09-25 1993-12-14 Gray Michael W Implantive ostomy ring
US5554389A (en) * 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5711969A (en) * 1995-04-07 1998-01-27 Purdue Research Foundation Large area submucosal tissue graft constructs
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
AU742457B2 (en) * 1996-08-23 2002-01-03 Cook Biotech, Incorporated Graft prosthesis, materials and methods
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
DE69734218T2 (de) * 1996-12-10 2006-07-06 Purdue Research Foundation, West Lafayette Gewebetransplantat aus der Magensubmukosa
US5993844A (en) * 1997-05-08 1999-11-30 Organogenesis, Inc. Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix
US7119062B1 (en) * 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
US7326571B2 (en) * 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
US8545386B2 (en) * 2003-08-14 2013-10-01 Boston Scientific Scimed, Inc. Surgical slings
US8874204B2 (en) * 2004-12-20 2014-10-28 Cardiac Pacemakers, Inc. Implantable medical devices comprising isolated extracellular matrix
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US8795384B2 (en) * 2007-01-10 2014-08-05 Cook Biotech Incorporated Implantable devices useful for reinforcing a surgically created stoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165983A (en) * 1991-07-31 2000-12-26 Klaus; Edwin Use of collagen for the treatment of degenerative articular processes
WO2005097219A2 (fr) * 2004-03-31 2005-10-20 Cook Incorporated Materiau de greffe a base d'ecm
WO2006034568A1 (fr) * 2004-09-30 2006-04-06 Covalon Technologies Inc. Matrices de gelatine elastiques non-adhesives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980296B2 (en) 2009-02-18 2015-03-17 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
US8845719B2 (en) 2011-05-27 2014-09-30 Cormatrix Cardiovascular, Inc Extracellular matrix material conduits and methods of making and using same
CN102698319A (zh) * 2012-03-02 2012-10-03 首都医科大学附属北京朝阳医院 一种抗肿瘤生物补片
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US11938246B2 (en) 2014-12-24 2024-03-26 Fettech, Llc Tissue-based compositions and methods of use thereof
WO2019113623A1 (fr) * 2017-12-11 2019-06-20 Animal Ethics Pty Ltd Pansement pour plaies
US11338055B2 (en) 2017-12-11 2022-05-24 Animal Ethics Pty Ltd Wound dressing
AU2018384069B2 (en) * 2017-12-11 2022-12-08 Animal Ethics Pty Ltd Wound dressing

Also Published As

Publication number Publication date
US20090142400A1 (en) 2009-06-04
WO2008151040A3 (fr) 2009-11-12

Similar Documents

Publication Publication Date Title
CA2667214C (fr) Materiaux de matrice extracellulaire traites presentant des profils de composants ameliores
US10500309B2 (en) Absorbable adhesives and their formulation for use in medical applications
US20090142400A1 (en) Analgesic coated medical product
CA2728553C (fr) Materiau de matrice extracellulaire isole comprenant un fascia sous-sereux
US20100266654A1 (en) Medical composition including an extracellular matrix particulate
AU2009259835B2 (en) Composite extracellular matrix materials and medical products formed therefrom
EP2326355B1 (fr) Procédé de production d'une colle à matrice acellulaire
JPH07116242A (ja) 医用材料及びその製造方法
CA2734336C (fr) Colle matricielle acellulaire
US10058631B2 (en) Tonsillectomy sponge
WO2010085449A1 (fr) Dispositif de fermeture de perforation de vaisseau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08756540

Country of ref document: EP

Kind code of ref document: A2